Multiple Myeloma

Establish the monoclonal protein and clone with serum protein electrophoresis, serum immunofixation, serum free light chains, and urine protein electrophoresis/immunofixation. Immunofixation identifies the immunoglobulin type, while serum free light-chain testing is particularly important when the clone produces little or no intact immunoglobulin; light-chain disease may be missed by serum electrophoresis alone.ScienceDirect+1ScienceDirectImmunofixation - an overview | ScienceDirect TopicsScienceDirectSerum Free Light-Chain Measurement - an overview

Obtain bone marrow aspirate and biopsy to quantify clonal plasma cells and assess cytogenetic risk, and image for osseous, marrow, and soft-tissue involvement. The diagnostic pivot is a clonal plasma-cell process with a myeloma-defining event rather than the mere presence of an M-protein.The Lancet+2The LancetSupplementary appendixScienceDirectRajshekhar ChakrabortyScienceDirectImmunofixation - an overview | ScienceDirect Topics

Classify as active myeloma when marrow clonal plasma cells are at least 10% or a biopsy-proven bony or extramedullary plasmacytoma is present plus attributable CRAB injury: calcium greater than 11 mg/dL, estimated GFR below 40 mL/min, anemia with hemoglobin at least 2 g/dL below normal, or myeloma-related bone disease. In the absence of CRAB injury, the IMWG biomarker-defined criteria are marrow plasma cells at least 60%, involved/uninvolved serum free light-chain ratio at least 100, or more than one MRI focal lesion at least 5 mm.ScienceDirect+2ScienceDirectRajshekhar ChakrabortyScienceDirectImmunofixation - an overview | ScienceDirect TopicsScienceDirectSLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis

In acute kidney injury, quantify serum free light chains and obtain serum and urine electrophoresis with immunofixation while evaluating competing renal diagnoses with urinalysis and urine sediment examination. KDIGO specifically includes serum free light chains and serum/urine electrophoresis-immunofixation in the evaluation of kidney disease when a monoclonal process is suspected.Kidney InternationalKidney InternationalKDIGO 2024 Clinical Practice Guideline for the Evaluation ... Symptomatic myeloma-associated acute kidney injury warrants coordinated nephrology and hematology management because renal dysfunction may reflect light-chain-mediated injury requiring prompt control of the plasma-cell clone.Kidney InternationalKidney InternationalManagement of acute kidney injury in symptomatic multiple ...

For hypercalcemia, establish whether the biochemical pattern is consistent with myeloma and identify immediate contributors such as dehydration and reduced renal function. A cited case of severe hypercalcemia with creatinine 2.7 mg/dL improved after hydration and bisphosphonate therapy, illustrating the need to correct volume depletion while lowering calcium in clinically significant disease.endocrineendocrineOR09-1

Use imaging to define myeloma-related bone disease, marrow involvement, and soft-tissue or extramedullary disease at baseline. Imaging is also relevant during follow-up when clinical or biochemical findings suggest progression, particularly when disease biology may become less reliably represented by a single serologic marker.The Lancet+1The LancetSupplementary appendixNatureCAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal

Document anemia, renal impairment, bone disease, and immunoparesis at presentation because these manifestations identify symptomatic disease and affect treatment tolerance. For patients being considered for CAR T-cell therapy later in their course, pre-lymphodepletion cytopenias and elevated CRP or ferritin identify a higher-risk group with longer severe neutropenia and substantially more severe infection.NatureNatureCAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal

For newly diagnosed active myeloma, induction with three drugs is generally superior to two drugs. Contemporary induction is moving toward quadruplets that combine a proteasome inhibitor, an immunomodulatory drug, a CD38-directed antibody, and dexamethasone for transplant-eligible patients.fda+1fdaMarch 15, 2024 - Current Management of Multiple MyelomaNatureToward a cure for multiple myeloma within a decade | Blood Cancer Journal Daratumumab is FDA-labeled in combination with lenalidomide and dexamethasone for newly diagnosed adult multiple myeloma, supporting its role in first-line combination treatment.dailymed nlm nihdailymed nlm nihDARZALEX

Assess autologous stem-cell transplant eligibility before finalizing the treatment sequence. In the trials summarized by the FDA, early transplant after RVd induction prolonged median progression-free survival compared with deferred transplant: 47.3 versus 35 months in IFM-2009 and 67.5 versus 46.2 months in DETERMINATION. Overall survival was similar in the reported comparisons, with 8-year survival of 62.2% versus 60.2% and 5-year survival of 80.7% versus 79.2%, respectively.fdafdaMarch 15, 2024 - Current Management of Multiple Myeloma This supports an individualized discussion of earlier disease control versus reserving transplant for relapse.

Maintenance therapy is a core component after initial therapy and transplantation in the FDA summary of current management, with lenalidomide used for two years in IFM-2009 and indefinitely in DETERMINATION.fdafdaMarch 15, 2024 - Current Management of Multiple Myeloma High-risk biology, frailty, organ dysfunction, baseline neuropathy, and treatment response should shape regimen selection and the intensity of follow-up rather than relying on transplant eligibility alone.Nature+1NatureCAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer JournalNatureA roadmap towards improving outcomes in multiple myeloma | Blood Cancer Journal

Minimal residual disease negativity is consistently associated with superior survival outcomes and is increasingly used as an efficacy endpoint, including in patients with high-risk cytogenetics. It should inform prognostic discussion and clinical-trial strategy, but MRD-guided discontinuation or de-escalation remains an evolving treatment paradigm.Nature+1NatureEHA–EMN Evidence-Based Guidelines for diagnosis, ...NatureA roadmap towards improving outcomes in multiple myeloma | Blood Cancer Journal

At each relapse, define refractoriness to lenalidomide, bortezomib, anti-CD38 therapy, and other prior classes before choosing the next regimen. The FDA treatment landscape lists lenalidomide-sensitive options such as KRd, DRd, ERd, and IRd; for lenalidomide-refractory but bortezomib-sensitive disease, it includes pomalidomide-based combinations such as DPd and IsaPd as well as proteasome inhibitor–based regimens such as DVd, DKd, IsaKd, KCd, CyBorD, and Kd.fdafdaMarch 15, 2024 - Current Management of Multiple Myeloma

For disease refractory to both lenalidomide and bortezomib, the listed options remain centered on pomalidomide-, carfilzomib-, and anti-CD38–containing combinations, including DPd, IsaPd, DKd, IsaKd, KCd, and KPd. Other listed approaches include selinexor-containing therapy, VD-PACE or VdCEP, cyclophosphamide-based regimens, and autologous transplant in selected circumstances.fdafdaMarch 15, 2024 - Current Management of Multiple Myeloma Use intensive cytoreductive regimens when the clinical tempo requires rapid control, not merely because the patient has accumulated prior lines.

Venetoclax is not FDA approved for multiple myeloma; the FDA management summary restricts its use to patients with t(11;14), including a venetoclax-bortezomib-dexamethasone option.fdafdaMarch 15, 2024 - Current Management of Multiple Myeloma Confirm t(11;14) before considering this targeted off-label strategy.

After refractoriness to an immunomodulatory drug, proteasome inhibitor, and anti-CD38 monoclonal antibody, refer promptly for BCMA-directed CAR T-cell therapy or T-cell–redirecting therapy planning. The FDA landscape lists idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab, talquetamab, and elranatamab in this heavily pretreated setting.fdafdaMarch 15, 2024 - Current Management of Multiple Myeloma

BCMA-directed CAR T-cell therapy is a major option for heavily pretreated relapsed/refractory myeloma. In the phase II KarMMa experience with idecabtagene vicleucel, overall response rate was 73%, complete response rate 33%, median progression-free survival 8.6 months, and median overall survival 24 months; the median time to first response was one month.NatureNatureCAR T therapies in multiple myeloma: unleashing the future | Cancer Gene Therapy These outcomes support referral before rapidly progressive disease, organ failure, or poor performance status complicate the pathway to cell therapy.

Expect cytokine-release syndrome and neurotoxicity after CAR T-cell infusion. In KarMMa, cytokine-release syndrome occurred in 84% of patients with a median onset of one day, while neurotoxicity occurred in 18% with a median onset of two days; grade 3 cytopenias were common.NatureNatureCAR T therapies in multiple myeloma: unleashing the future | Cancer Gene Therapy Build monitoring capacity around early postinfusion inflammatory and neurologic complications and anticipate prolonged hematologic support needs.

Extramedullary disease and high-risk cytogenetics predict poorer CAR T-cell outcomes. A meta-analysis summarized in a contemporary review found extramedullary disease associated with a 44% higher risk of relapse, progression, or death after CAR T-cell treatment; high-risk cytogenetics reduced overall response rate and increased the risk of progression, relapse, or death by 70%.NatureNatureCAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal These factors should prompt realistic counseling and consideration of clinical trials or alternate sequencing strategies.

Pre-lymphodepletion cytopenias plus elevated CRP or ferritin identify a clinically important high-risk toxicity phenotype: severe neutropenia lasted 9 versus 3 days, severe infection occurred in 40% versus 5%, and one-year non-relapse mortality was 13% versus 2% compared with lower-risk patients.NatureNatureCAR-T cell therapy in Multiple Myeloma: current status and future challenges | Blood Cancer Journal Obtain CBC, CRP, and ferritin during candidacy assessment and use the result to intensify infection-risk planning and post-treatment surveillance.